初始接受顺铂治疗的癌症患者尿肾衰竭生物标志物的差异。
Differences in Urinary Renal Failure Biomarkers in Cancer Patients Initially Treated with Cisplatin.
作者信息
Maeda Akimitsu, Ando Hitoshi, Ura Takashi, Muro Kei, Aoki Masahiro, Saito Ken, Kondo Eisaku, Takahashi Shinji, Ito Yuko, Mizuno Yasunari, Fujimura Akio
机构信息
Department of Pharmacy, Aichi Cancer Center Hospital, Nagoya, Japan
Division of Clinical Pharmacology, Department of Pharmacology, Jichi Medical University, Tochigi, Japan.
出版信息
Anticancer Res. 2017 Sep;37(9):5235-5239. doi: 10.21873/anticanres.11947.
BACKGROUND/AIM: We investigated whether measuring the excretion of each acute kidney injury (AKI) biomarker after cisplatin (CDDP) administration is useful for predicting AKI and evaluated the most appropriate AKI marker in patients treated with CDDP.
PATIENTS AND METHODS
We measured NAG, Kim-1, and NGAL in urinary samples of 40 cancer patients treated with chemotherapy on day 1 (before chemotherapy), day 2, and day 5 after treatment; serum creatinine (sCr) was compared on days 7 and 28 after CDDP administration vs. baseline.
RESULTS
NAG, Kim-1, and NGAL excretion (creatinine corrected) were not significantly elevated 5 days after receiving chemotherapy in the non-CDDP chemotherapy group. Conversely, all markers were significantly higher 5 days after receiving chemotherapy in the CDDP group when compared to baseline.
CONCLUSION
Urinary NAG, Kim-1, and NGAL can detect renal injury more sensitively than sCr.
背景/目的：我们研究了顺铂（CDDP）给药后测量每种急性肾损伤（AKI）生物标志物的排泄量是否有助于预测AKI，并评估了接受CDDP治疗患者中最合适的AKI标志物。
患者与方法
我们在40例接受化疗的癌症患者化疗第1天（化疗前）、第2天和治疗后第5天的尿液样本中测量了NAG、Kim-1和NGAL；比较了CDDP给药后第7天和第28天与基线时的血清肌酐（sCr）。
结果
在非CDDP化疗组中，化疗后5天NAG、Kim-1和NGAL排泄量（肌酐校正）无显著升高。相反，与基线相比，CDDP组化疗后5天所有标志物均显著升高。
结论
尿NAG、Kim-1和NGAL比sCr能更敏感地检测肾损伤。
Zotero 插件